Undisclosed KRAS G12D inhibitor / BMS - LARVOL DELTA

Dr Jänne on the Investigation of RMC-6291 in KRAS G12C-Mutated Solid Tumors (OncLive) - P1/b | N=117 | (NCT05462717) | Sponsor: Revolution Medicines, Inc. | "Pasi A. Janne, MD, PhD, discusses the mechanism of action of the novel KRAS G12C RAS(ON) inhibitor RMC-6291, which is being evaluating for the treatment of patients with KRAS-mutated solid tumors."

P1 data • Video

KRAS G12C Inhibitors: Durability of Response, Efficacy in Combination, in NSCLC (THE ASCO POST) - ''In the current pooled analysis with longer follow-up, adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at 2 years,' said Shirish Gadgeel, MBBS....A confirmatory phase III study-KRYSTAL-12-is evaluating adagrasib vs docetaxel in previously treated patients in North America, Europe, Asia, and Australia."

Media quote

#Targets23 Dr. @AlexSpiraMDPhD presents early look at RMC-6236, a first-in-class RAS(ON) inhibitor in #KRAS tumors. Safety data very reassuring and example of response in KRAS G12D pancreatic cancer and KRAS G12D NSCLC! Huge unmet need, very exciting - await data at #ESMO23!